Partnership between Institut Curie and Harmonic Pharma
As part of this partnership, Institut Curie will enable Harmonic Pharma to use the large collection of primary xenotransplants representative of human tumors of the Institut Curie explore the anti-cancer activity of several molecules in his portfolio.
Harmonic Pharma is a young innovative company whose main activity is to identify, through a molecular repositioning approach, new therapeutic uses for already known molecules.
"It is very important for us to rely on a major internationally recognized center such as the Institut Curie to access experimental models, know-how and basic knowledge on cancer development," said Michel Souchet, CEO of Harmonic Pharma.
"We quickly moved to three types of models for which we have a wide variety of tumors and a fairly long experience: breast cancers, lung cancers, and eye cancers," says Didier Decaudin, who heads the preclinical research laboratory of Institut Curie.
For this long-term collaboration, the costs will be shared between the two partners. Depending on the results obtained, some of the molecules studied can be taken over by Curie-Cancer for clinical studies for the benefit of patients.